Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanoma

References

• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med InternetAvailable from. 1988;319:1676–1680. DOI:10.1056/NEJM198812223192527
   PubMed Web of Science ®Google Scholar
• Chesney JA, Schoenfeld AJ, Wise-Draper T, et al. Abstract CT130: trial in progress: a phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating lymphocyte (TIL) cell therapy (LN-145) in patients with metastatic non-small cell lung cancer (mNSCLC). Cancer Res. 2022;82:CT130.
   Google Scholar
• Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39:2656–2666.
   PubMed Web of Science ®Google Scholar
• Rayner AA, Grimm EA, Lotze MT, et al. Lymphokine-Activated Killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. JNCI. 1985;75:67–75. InternetAvailable from. DOI:10.1093/jnci/75.1.67
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233–240.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. JNCI. 1994;86:1159–1166.
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16:2646–2655.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18:6758–6770.
   PubMed Web of Science ®Google Scholar
• Andersen R, Donia M, Ellebaek E, et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res. 2016;22:3734–3745.
   PubMed Web of Science ®Google Scholar
• Ellebaek E, Iversen TZ, Junker N, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med. 2012;10:169.
   PubMed Web of Science ®Google Scholar
• Haanen J, Rohaan M, Borch TH. LBA3 - Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: results from a multicenter, randomized phase III trial. Ann Oncol. 2022;33:S808–869. DOI:10.1016/j.annonc.2022.08.036
   Web of Science ®Google Scholar
• Draghi A, Chamberlain CA, Furness A, et al. Acquired resistance to cancer immunotherapy. Semin Immunopathol. 2019;41:31–40.
   PubMed Web of Science ®Google Scholar
• O’malley D, Lee S, Psyrri A, et al. 492 phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers. J Immunother Cancer. 2021;9:A523. Internet Available from http://jitc.bmj.com/content/9/Suppl_2/A523.abstract
   Web of Science ®Google Scholar
• O’malley D Phase 2 efficacy and safety of autologous Tumor-Infiltrating Lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers. SITC 2021 [Internet]. (WA) DC; 2021. Available from: https://www.iovance.com/scientific-publications-presentations/. [cited 2022Dec6].
   Google Scholar
• Kristensen NP, Heeke C, Tvingsholm SA, et al. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. J Clin Investig. 2022;132. DOI:10.1172/JCI150535
   Web of Science ®Google Scholar
• Lauss M, Donia M, Harbst K, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8:1738.
   PubMed Web of Science ®Google Scholar
• Turajlic S, Jamal-Hanjani M, Furness A, et al. 543 sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNet) therapy: from manufacture to peripheral circulation. J Immunother Cancer. 2021;9:A572. InternetAvailable from https://jitc.bmj.com/content/9/Suppl_2/A572
   Web of Science ®Google Scholar
• Yossef R, Tran E, Deniger DC, et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight. 2018;3. DOI:10.1172/jci.insight.122467
   PubMed Web of Science ®Google Scholar
• Warner A. Trial in progress: a phase 1/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC. SITC. Boston; 2022.
   Google Scholar
• Tran E, Robbins PF, Rosenberg SA. “Final common pathway” of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18:255–262. DOI:10.1038/ni.3682
   PubMed Web of Science ®Google Scholar
• Menger L, Sledzinska A, Bergerhoff K, et al. TALEN-Mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral t-cell persistence and rejection of established tumors. Cancer Res. 2016;76:2087–2093.
   PubMed Web of Science ®Google Scholar
• Pal S, Tran B, Haanen J, et al. 558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: results from the phase 1 COBALT-RCC study. Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2022; p. A584.
   Google Scholar
• Wolf B, Zimmermann S, Arber C, et al. Safety and Tolerability of Adoptive Cell Therapy in Cancer. Drug Saf. 2019;42:315–334.
   PubMed Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22:433–438.
   PubMed Web of Science ®Google Scholar
• Gros A, Tran E, Parkhurst MR, et al. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. J Clin Investig. 2019;129:4992–5004.
   PubMed Web of Science ®Google Scholar
• Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479–485.
   PubMed Web of Science ®Google Scholar
• Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10:e005755.
   PubMed Web of Science ®Google Scholar
• van den Berg JH, Heemskerk B, van Rooij N, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer. 2020;8:e000848.
   PubMed Web of Science ®Google Scholar